[Form 4] Autonomix Medical, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Brad Hauser, identified as an officer (CEO and President) of Autonomix Medical, Inc. (AMIX), reported a transaction with an earliest transaction date of 08/11/2025.

The filing discloses a derivative option that represented the right to buy 45,000 shares of common stock with an exercise price of $27, exercisable beginning 06/17/2025 and expiring 06/17/2034. The option was cancelled by mutual agreement, and the reporting person received three months' severance as consideration. The Form 4 is signed by an attorney-in-fact on behalf of Brad Hauser dated 08/13/2025.

Positive

• Option cancellation was resolved by mutual agreement, indicating the matter was settled consensually
• Reporting person received three months' severance as explicit consideration for the cancellation

Negative

• Cancellation removes potential equity upside tied to an option for 45,000 shares
• Filing does not disclose monetary amount of severance or additional details, so company financial impact is not quantified in the Form 4

Insights

Corporate Governance Expert

TL;DR: A 45,000-share option held by the CEO was cancelled by mutual agreement; three months' severance was paid as consideration.

The filing documents a negotiated cancellation of a derivative award that would have converted into 45,000 common shares at a $27 exercise price. The disclosure is explicit that the option was revised previously for a 1-for-20 reverse split and then cancelled, with severance provided as consideration. From a governance perspective, the record shows a contractual resolution recorded on Form 4, but the filing does not state any change in employment status or other ancillary arrangements beyond the severance payment.

Securities / Insider Transactions Analyst

TL;DR: The transaction is a clear insider option cancellation; the immediate reported impact is limited to the loss of the option and a cash-equivalent severance.

The Form 4 reports a derivative security (option) tied to 45,000 common shares was cancelled effective with an 08/11/2025 transaction date. The option had a stated exercise price of $27 and specified exercisability and expiration dates. The filing states the reporting person received three months' severance as consideration for cancellation. The document does not disclose any cash amount, departure, or additional compensation beyond the severance statement, so quantified financial impact on the company is not provided in the filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hauser Bradley

(Last) (First) (Middle)

C/O AUTONOMIX MEDICAL, INC.

21 WATERWAY AVENUE, SUITE 300

(Street)

THE WOODLANDS TX 77380

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Autonomix Medical, Inc. [ AMIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and President

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (Right to buy)	$27(1)	08/11/2025		D			45,000(1)	06/17/2025	06/17/2034	Common Stock	45,000	(1)	0	D

Explanation of Responses:

1. Option represents a revised share amount and exercise price based on a 1-for-20 reverse stock split from October 25, 2024. The option was cancelled by mutual agreement of the reporting person and the Company. The reporting person received three months severance as consideration for the cancellation.

	/s/ Trent Smith, Attorney-in-Fact for Brad Hauser	08/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for Autonomix Medical (AMIX)?

Brad Hauser, listed as an officer (CEO and President) of Autonomix Medical, Inc., filed the Form 4 via attorney-in-fact.

What transaction is reported on the AMIX Form 4 dated 08/11/2025?

An option to buy 45,000 shares (exercise price $27) was cancelled by mutual agreement, with the transaction date reported as 08/11/2025.

What consideration did the reporting person receive for the cancellation?

The filing states the reporting person received three months' severance as consideration for the option cancellation.

How many derivative securities does the reporting person own after the transaction?

The Form 4 indicates the option representing 45,000 underlying shares was cancelled, and the filing reports no remaining derivative securities

What were the exercisability and expiration dates of the cancelled option?

The option was exercisable beginning 06/17/2025 and had an expiration date of 06/17/2034, per the filing.

When was the Form 4 signed and by whom?

The signature block shows /s/ Trent Smith, Attorney-in-Fact for Brad Hauser with a signature date of 08/13/2025.